Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2015

View Archived Issues

Cantargia licenses use of BioWa's Potelligent platform to produce CAN-04

Investigators develop and characterize a novel series of anticoronavirus agents

Immunocore and Lilly collaborate to study immunotherapies for melanoma

Actelion and Max Planck Society form new start-up Vaxxilon

Amarna Therapeutics partners with CBmed on development of immunotherapies

Taisho and Ablynx sign exclusive license agreement for ozoralizumab in Japan

Herantis Pharma granted European government loan for Parkinson's study

Safety board recommends phase III rindopepimut study continue

Scientists disclose phase I results for PepCan

Clinical endpoints met in phase II study of P2B-001 in early Parkinson's disease

MK-1439A enters two new phase III studies in HIV

Preclinical data of SIRM antibody support further development

KBP-089: an antiobesity dual amylin and calcitonin receptor agonist

AMAG to acquire Cord Blood Registry

Entasis debuts with a portfolio of drug candidates to treat drug-resistant infections

Teva and Xenon provide update on TV-45070 phase IIb study in osteoarthritis pain

GlaxoSmithKline presents phase Ib results of GSK-2256098

Panther Biotechnology to acquire Alchemia Oncology

Results from metformin arm of phase II trial of BI-187004

Sun Biomedical reports conditions met for acquisition of Dimerix

Allergan discloses S1P1 receptor modulators

Genentech presents ERK inhibitors

Ignyta's new clinical trial assay to support STARTRK program for entrectinib

Prolong's novel ANF compound for hematopoiesis deficiencies

Biogen and Sunesis patent BTK inhibitors

FDA extends review of cobimetinib NDA

Gilead submits NDA for emtricitabine/rilpivirine/tenofovir alafenamide in HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...